Temsirolimus in the treatment of advanced renal cell carcinoma

Oncology Reviews

Volumn 1, Issue 2, 2007, Pages 73-80

  Escudier, Bernard J ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Kidney cancer; MTOR; Renal cell carcinoma; Targeted therapy; Temsirolimus

Indexed keywords

EID: 65349144391     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.1007/s12156-007-0009-2     Document Type: Review

References (65)

1. Kjaer M, Frederiksen PL, Engelholm SA (1987) Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys 13:665-672
2. Minasian LM, Motzer RJ, Gluck L et al (1993) Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11:1368-1375 (Pubitemid 23199143)
3. Yagoda A, bi-Rached B, Petrylak D (1995) Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 22:42-60
4. Yang JC, Sherry RM, Steinberg SM et al (2003) Randomized study of highdose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21:3127-3132 (Pubitemid 46606294)
5. Motzer RJ, Bukowski RM (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24:5601-5608 (Pubitemid 46631341)
6. Iliopoulos O (2006) Molecular biology of renal cell cancer and the identification of therapeutic targets. J Clin Oncol 24:5593-5600 (Pubitemid 46631340)
7. Motzer R, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124 (Pubitemid 46089672)
8. Escudier B, Eisen T, Stadler W et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134 (Pubitemid 46089673)
9. Dudkin L, Dilling MB, Cheshire PJ et al (2001) Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumour growth inhibition. Clin Cancer Res 7:1758-1764 (Pubitemid 32708646)
10. Guba M, von Breitenbuch P, Steinbauer M et al (2002) Rapamycin inhibits primary and metastatic tumour growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128-135 (Pubitemid 34155123)
11. Huang S, Houghton PJ (2003) Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 3:371-377 (Pubitemid 36908940)
12. Thomas GV, Tran C, Mellinghoff IK et al (2006) Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12:122-127 (Pubitemid 43050086)
13. Mamane Y, Petroulakis E, Lebacquer O et al (2006) mTOR, translation initiation and cancer. Oncogene 25:6416-6422 (Pubitemid 44582285)
14. Del Bufalo D, Ciuffreda L, Trisciuoglio D et al (2006) Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66:5549-5554 (Pubitemid 43927103)
15. Sabers CJ, Martin MM, Brunn GJ et al (1995) Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 270:815-822
16. Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335-348 (Pubitemid 38579480)
17. Patel PH, Chadalavada RS, Chaganti RS et al (2006) Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 12:7215-7220 (Pubitemid 46095391)
18. Brown EJ, Beal PA, Keith CT et al (1995) Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 377:441-446
19. Brunn GJ, Hudson CC, Sekulic A et al (1997) Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277:99-101 (Pubitemid 27450655)
20. Lazaris-Karatzas A, Montine KS, Sonenberg N (1990) Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature 345:544-547
21. Rousseau D, Kaspar R, Rosenwald I et al (1996) Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc Natl Acad Sci U S A 93:1065-1070 (Pubitemid 26054368)
22. Arsham AM, Howell JJ, Simon MC (2003) A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 278:29655-29660 (Pubitemid 36962350)
23. Connolly E, Braunstein S, Formenti S et al (2006) Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol Cell Biol 26:3955-3965 (Pubitemid 43726410)
24. Liu L, Cash TP, Jones RG et al (2006) Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell 21:521-531 (Pubitemid 43228007)
25. Gnarra JR, Tory K, Weng Y et al (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85-90 (Pubitemid 24232386)
26. Kim WY, Kaelin WG (2004) Role of VHL gene mutation in human cancer. J Clin Oncol 22:4991-5004 (Pubitemid 46646218)
27. Maranchie JK, Vasselli JR, Riss J et al (2002) The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1:247-255 (Pubitemid 41039149)
28. Ohh M, Park CW, Ivan M et al (2000) Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2:423-427
29. Calne RY, Collier DS, Lim S et al (1989) Rapamycin for immunosuppression in organ allografting. Lancet 2(8656):227
30. Dutcher JP (2004) Mammalian target of rapamycin inhibition. Clin Cancer Res 10:6382S-6387S (Pubitemid 39287496)
31. Huang S, Liu LN, Hosoi H et al (2001) p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Res 61:3373-3381 (Pubitemid 32695028)
32. Decker T, Hipp S, Ringshausen I et al (2003) Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 101:278-285 (Pubitemid 36025919)
33. Luo Y, Marx SO, Kiyokawa H et al (1996) Rapamycin resistance tied to defective regulation of p27Kip1. Mol Cell Biol 16:6744-6751 (Pubitemid 26389733)
34. Morice WG, Brunn GJ, Wiederrecht G et al (1993) Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes. J Biol Chem 268:3734-3738 (Pubitemid 23071022)
35. Yu K, Toral-Barza L, Discafani C et al (2001) mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8:249-258 (Pubitemid 32947647)
36. Chang SM, Kuhn J, Wen P et al (2004) Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs 22:427-435 (Pubitemid 39619819)
37. Raymond E, Alexandre J, Faivre S et al (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336-2347 (Pubitemid 41115390)
38. Hidalgo M, Buckner JC, Erlichman C et al (2006) A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 12:5755-5763 (Pubitemid 44629606)
39. Rao RD, Windschitl HE (2006) Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastice melanoma. J Clin Oncol 24[Suppl 18]:8043
40. Porter LL, Burris HA, Jones SF et al (2006) Summary of results in patients with metastic renal cell cancer (RCC) from phase I studies of RAD001 (everolimus). J Clin Oncol 24[Suppl 18]:14599
41. Chawla SP, Tolcher AW, Staddon AP et al (2006). Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas. J Clin Oncol 24[Suppl 18]:9505
42. Gibbons JJ (2006) CCI-779 potentiates the inhibitory effect of the anti-angiogenesis drug interferon-alpha on the growth of a human renal cell carcinoma in nude mice. RPT-49843. Pearl River, NY: Wyeth Research
43. Shi Y, Gera J, Hu L et al (2002) Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 62:5027-5034 (Pubitemid 34984430)
44. Wan X, Shen N, Mendoza A et al (2006) CCI-779 Inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/HIF-1alpha/VEGF signaling. Neoplasia 8:394-401 (Pubitemid 43830746)
45. Wislez M, Spencer ML, Izzo JG et al (2005) Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic Kras. Cancer Res 65:3226-3235 (Pubitemid 40524605)
46. Wu L, Birle DC, Tannock IF (2005) Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 65:2825-2831 (Pubitemid 40490085)
47. Teachey DT, Obzut DA, Cooperman J et al (2006) The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 107:1149-1155 (Pubitemid 43156317)
48. Boni JP, Leister C, Bender G et al (2005) Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther 77:76-89 (Pubitemid 40075391)
49. Atkins MB, Hidalgo M, Stadler WM et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909-918 (Pubitemid 41103603)
50. Punt CJ, Boni J, Bruntsch U et al (2003) Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumours. Ann Oncol 14:931-937 (Pubitemid 36827210)
51. Forouzesh B, Buckner J, Adjei A et al (2002) Phase 1, bioavailability, and pharmacokinetic study of oral dosage of CCI-779 administered to patients with advanced solid malignancies. Eur J Cancer 38 [Suppl 7]:S54
52. Smith JW, Ko Y-J, Dutcher J et al (2004) Update of a phase 1 study of intravenous CCI-779 given in combination with interferon-α to patients with advanced renal cell carcinoma. J Clin Oncol 22 [Suppl 14]:S4513
53. Haas NB, Lewis N, Cohen RB et al (2006) Phase 1 study of intravenous CCI-779 in combination with bryostatin-1 in solid tumours. J Clin Oncol 24 [Suppl 18]: 3067
54. Zimmerman JJ (2004) Exposureresponse relationships and drug interactions of sirolimus. AAPS J 6:e28
55. Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434 (Pubitemid 36910021)
56. Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512 (Pubitemid 46630627)
57. Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296 (Pubitemid 34032623)
58. Duran I, Siu LL, Oza AM et al (2006) Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 42:1875-1880 (Pubitemid 44149096)
59. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281 (Pubitemid 46849157)
60. Dutcher JP, Hudes G, Motzer R et al (2003) Preliminary report of a phase 1 study of intravenous (IV) CCI-779 given in combination with interferon-α (IFN) to patients with advanced renal cell carcinoma (RCC) J Clin Oncol 22:Abstract 854
61. Chang DZ, Olencki T, Budd GT et al (2001) Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics. Cancer Chemother Pharmacol 48:493-498 (Pubitemid 33139872)
62. Bukowski RM, Kabbinava F, Figlin RA (2006) Bevacizumab with or without erlotinib in metastatic renal cell carcinoma. J Clin Oncol 18S:Abstract 4523
63. Pantuck AJ, Zeng G, Belldegrun AS et al (2003) Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 9:4641-4652 (Pubitemid 37323266)
64. Kim DH, Sarbassov DD, Ali SM et al (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110:163-175 (Pubitemid 34876545)
65. Brunet A, Bonni A, Zigmond MJ et al (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857-868 (Pubitemid 29165088)